Welcome to our dedicated page for Guardant Health SEC filings (Ticker: GH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Guardant Health, Inc. filings document a Nasdaq-listed precision oncology company that reports results for Oncology, Screening, and Biopharma & Data activities. Its 8-K filings furnish quarterly and annual financial results, preliminary financial information, Regulation FD presentation materials, material agreements, officer changes, and securities offering disclosures.
The company’s proxy materials cover annual meeting voting matters, board and governance information, executive compensation and stockholder proposals. Registration and offering-related filings describe common stock issuance under a shelf registration statement, while recurring disclosures address capital structure, operating outlook, clinical and regulatory updates, and the use of its blood and tissue testing portfolio.
Guardant Health, Inc. director Manuel Hidalgo Medina reported an open-market sale of 1,000 shares of Common Stock at an average price of $130.0601 per share. After this transaction on May 28, 2026, he directly holds 639 shares of Guardant Health common stock.
Guardant Health, Inc. Chief Legal Officer John G. Saia reported selling 10,000 shares of common stock in open-market transactions on May 27, 2026. The filing shows two sales: 6 shares at $126.08 per share and 9,994 shares at $125.083 per share.
A footnote explains that the reported price reflects a weighted average, with individual trades executed between $125.00 and $125.44 per share. The insider remains a shareholder after these sales, but the exact remaining position is not detailed in the provided data.
Guardant Health lists a proposed sale of 1,000 shares of Common stock. The filing states the sale relates to a restricted stock lapse dated 10/17/2025 and is identified as equity compensation. The excerpt also shows past sales by Manuel Hidalgo Medina: 1,300 shares on 03/06/2026 for $118,997.00 and 1,250 shares on 05/20/2026 for $133,864.00.
Guardant Health Chief Commercial Officer Chris Freeman exercised options to acquire 24,406 shares of common stock at $32.86 per share and on the same day completed an open-market sale of 24,406 shares at a weighted average price of $118.6741.
After these transactions, Freeman directly holds 60,034 shares of common stock and 701 remaining stock options with a $32.86 exercise price expiring on June 9, 2033. The exercised options come from a June 9, 2023 award that vests over three years.
Guardant Health, Inc. reported a Form 144 notice regarding the sale resulting from an employee stock option exercise on 05/22/2026. The transaction was handled via Charles Schwab & Co., Inc. as a broker payment for cashless exercise of common stock.
Guardant Health, Inc. Chief Legal Officer John G. Saia reported open-market sales of a total of 20,000 shares of common stock on May 20, 2026. The shares were sold in three separate transactions at weighted average prices around $105–$107 per share, each executed across multiple trades within narrow intraday price ranges. These transactions reduce his direct holdings but he continues to own Guardant Health stock after the sales.
Guardant Health, Inc. disclosed that the Talasaz and Eskandari 2017 Family Trust, an entity associated with Co-Chief Executive Officer AmirAli Talasaz, completed a series of open-market sales of the company’s common stock.
The filing shows that the trust sold a total of 210,000 shares of Guardant Health common stock on May 20, 2026, across multiple trades. Reported weighted-average sale prices ranged from about $100.95 to about $112.76 per share, with detailed trade-by-trade pricing available on request from the company or the SEC staff. Following these transactions, the trust held 2,096,304 shares of Guardant Health common stock indirectly attributable to Talasaz.
Guardant Health, Inc. director Ian T. Clark reported an indirect open-market sale of the company’s Common Stock. On May 20, 2026, a family trust associated with him sold 6,876 shares at a weighted average price of $106.9006 per share, in multiple trades between $106.85 and $106.99. Following the transaction, the trust held 2,975 shares of Guardant Health Common Stock indirectly on his behalf, and no derivative securities were reported in this filing.
Guardant Health director Manuel Hidalgo Medina reported an option exercise and related stock sales. On May 20, 2026, he exercised stock options to acquire 1,000 shares of common stock at an exercise price of $32.55 per share.
That same day, he completed open-market sales totaling 1,250 shares of common stock, including 250 shares at a weighted-average price of $107.073 per share and 1,000 shares at $107.0956 per share. After these transactions, he directly holds 1,639 shares of Guardant Health common stock and 13,029 stock options with a $32.55 exercise price that expire on July 17, 2034.